Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

It is finally bouncing back after several challenging years.

Can the drugmaker justify its valuation?

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...